Autopsy report · NCT00102128

Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.

“DMC recommended stop”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 2 months after it had already started.
• Ran for about 4 years 5 months before it stopped.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Genzyme, a Sanofi Company

Sponsor type

Industry

Conditions

Ischemic Heart Failure; Ischemic Heart Disease; Ischemic Cardiomyopathy

Interventions

Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)

Sites

28

Countries

Belgium, France, Germany, Italy, Switzerland, United Kingdom

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.